Join us for an exclusive discussion with Nicola Normanno, MD, scientific director at the Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRCCS and president of IQN Path, as he shares cutting-edge insights from the forefront of precision oncology.
Drawing from the landmark RATIONAL study and his pioneering work harmonizing molecular testing across Europe, Normanno will explore how comprehensive genomic profiling (CGP) is revolutionizing cancer treatment—from detecting unexpected germline alterations to enabling liquid biopsy-guided therapy decisions when tissue is scarce.
What You’ll Learn:
• The Implementation Reality Check: Despite legislative advances, less than 2% of Italian cancer patients currently access NGS testing. Discover why this critical gap exists and how to close it
• Proven Partnership Models: Innovative public-private strategies that democratize access and eliminate the “post-code lottery” between northern and southern Italy
• Your Global Blueprint: How Italy’s lessons can be transferred to other EU countries and beyond to the U.S., serving as a roadmap for healthcare systems worldwide
• Community Hospital Solutions: Build CGP capabilities without major infrastructure investments
• The Economics of Precision: Why precision medicine may be the key to containing healthcare costs, not driving them
• Regulatory Transformation: How real-world evidence from initiatives like RATIONAL is reshaping policy frameworks
From complex molecular tumor board cases to the future of multi-omics and AI-driven early detection, this conversation delivers essential, actionable insights for oncologists, pathologists, and healthcare leaders navigating the evolving landscape of precision cancer care.
Don’t miss this opportunity to learn from one of Europe’s most influential voices in translational oncology!
Produced with support from:
